Addiction Medicine Research Priorities ASAM 2022

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), and Agency for Healthcare Research and Quality (AHRQ) have requested input from ASAM members on how to improve the clinical relevance of their addiction medicine research portfolios. Please provide input on their questions below, and add any questions or comments you may have at the end of the form. We will also discuss these questions at the "Bridging the Gap between Science and Clinical Practice in Addiction Medicine" session during the ASAM 2022 conference. If you have any questions, please email Ray Denny, PhD, Associate Director of Science, at rdenny@asam.org. Thank you!

Select or enter value
Caret IconCaret symbol

What barriers to screening, brief intervention and referral to addiction treatment that you most often encounter in your clinical practice?

To what extent would a panel of biomarkers for compromised liver function be useful to help diagnose moderate to severe AUD?

What would help to reduce stigma for treatment of AUD in clinical practice?

Recruitment for clinical trials has been negatively impacted during the pandemic. What would you do to enhance recruitment?

From your perspective and experience, what are the biggest evidence gaps in treating addiction?

How can ASAM work with NIDA/NIH to promote greater diversity in practitioner and clinical research?

What is one idea that runs counter to conventional wisdom or typical practice that you think would make a difference in treating addiction?

What are the most effective policies or practices you have found for retaining patients on MOUD in treatment?

What are some ways you currently care for social needs of individuals with SUD or successful models that you’ve heard of?

What are the biggest challenges you face in treating patients with polysubstance use?

Powered by Smartsheet Modern Logo On Light
Privacy Notice|Report Abuse